Multiple Sclerosis News

WEST PALM BEACH, Fla. — Large language model algorithms may be reliable for synthesizing large patient databases to more rapidly and accurately diagnose multiple sclerosis, according to a poster presented at ACTRIMS.

WEST PALM BEACH, Fla. — Treatment with fampridine may positively impact patients with multiple sclerosis who are recovering from optic neuritis, but more extensive clinical trials are required to fully assess its effectiveness, according to a poster at ACTRIMS.

WEST PALM BEACH, Fla. — A machine learning model using existing clinical data may help clinicians screen for comorbid anxiety and depression in patients with multiple sclerosis, according to a poster presented at ACTRIMS.

WEST PALM BEACH, Fla. — Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show.

WEST PALM BEACH, Fla. — A 6-month ketogenic diet and 2-month calorie-restricted diet were associated with significant reductions in biological age in patients with relapsing-remitting multiple sclerosis, according to a poster at ACTRIMS.

WEST PALM BEACH, Fla. — Real-world effects of ublituximab after 1 year of administration were consistent with data from a pair of phase 3 clinical trials investigating the drug, according to a poster presented at ACTRIMS.

WEST PALM BEACH, Fla. — Researchers have identified a positive association between multiple sclerosis and ADHD, as well as a trend toward an earlier diagnosis of MS among those with ADHD, according to a poster presented at ACTRIMS.

WEST PALM BEACH, Fla. — It may be sensible for older patients with MS who have prolonged stability to cease disease-modifying therapy, but more data are needed to understand the effects of discontinuation in this group, an expert said.

WEST PALM BEACH, Fla. — For patients with MS, the risk for disability worsening was reduced with physical activity, highlighting the importance of recommending it in practice, researchers reported at ACTRIMS.

WEST PALM BEACH, Fla. — A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients with MS who participated in phase 3 clinical trials of disease-modifying therapies, data show.